RESUMEN
Alveolar bone loss is a result of an aggressive form of periodontal disease (PD) associated with Aggregatibacter actinomycetemcomitans (Aa) infection. PD is often observed with other systemic inflammatory conditions, including arthritis. Melanocortin peptides activate specific receptors to exert antiarthritic properties, avoiding excessing inflammation and modulating macrophage function. Recent work has indicated that melanocortin can control osteoclast development and function, but whether such protection takes place in infection-induced alveolar bone loss has not been investigated. The purpose of this study was to evaluate the role of melanocortin in Aa-induced PD. Mice were orally infected with Aa and treated with the melanocortin analog DTrp8-γMSH or vehicle daily for 30 d. Then, periodontal tissue was collected and analyzed. Aa-infected mice treated with DTrp8-γMSH presented decreased alveolar bone loss and a lower degree of neutrophil infiltration in the periodontium than vehicle-treated animals; these actions were associated with reduced periodontal levels of TNF-α, IFN-γ, and IL-17A. In vitro experiments with cells differentiated into osteoclasts showed that osteoclast formation and resorptive activity were attenuated after treatment with DTrp8-γMSH. Thus, melanocortin agonism could represent an innovative way to tame overexuberant inflammation and, at the same time, preserve bone physiology, as seen after Aa infection.-Madeira, M. F. M., Queiroz-Junior, C. M., Montero-Melendez, T., Werneck, S. M. C., Corrêa, J. D., Soriani, F. M., Garlet, G. P., Souza, D. G., Teixeira, M. M., Silva, T. A., Perretti, M. Melanocortin agonism as a viable strategy to control alveolar bone loss induced by oral infection.
Asunto(s)
Pérdida de Hueso Alveolar/prevención & control , Melanocortinas/agonistas , Osteoclastos/microbiología , Infecciones por Pasteurellaceae/prevención & control , Enfermedades Periodontales/metabolismo , Aggregatibacter actinomycetemcomitans , Pérdida de Hueso Alveolar/etiología , Animales , Diferenciación Celular/efectos de los fármacos , Diferenciación Celular/fisiología , Macrófagos/inmunología , Ratones Endogámicos C57BL , Periodontitis/tratamiento farmacológico , Periodontitis/metabolismoRESUMEN
INTRODUCTION: Female sexual function reflects a dynamic interplay of central and peripheral nervous, vascular, and endocrine systems. The primary challenge in the development of novel treatments for female sexual dysfunction is the identification and targeted modulation of excitatory sexual circuits using pharmacologic treatments that facilitate the synthesis, release, and/or receptor binding of neurochemicals, peptides, and hormones that promote female sexual function. AIM: To develop an evidence-based state-of-the-art consensus report that critically integrates current knowledge of the therapeutic potential for known molecular and cellular targets to facilitate the physiologic processes underlying female sexual function. METHODS: State-of-the-art review representing the opinions of international experts developed in a consensus process during a 1-year period. MAIN OUTCOME MEASURES: Expert opinion was established by grading the evidence-based medical literature, intensive internal committee discussion, public presentation, and debate. RESULTS: Scientific investigation is urgently needed to expand knowledge and foster development of future treatments that maintain genital tissue integrity, enhance genital physiologic responsiveness, and optimize positive subjective appraisal of internal and external sexual cues. This article critically condenses the current knowledge of therapeutic manipulation of molecular and cellular targets within biological systems responsible for female sexual physiologic function. CONCLUSION: Future treatment targets include pharmacologic modulation of emotional learning circuits, restoration of normal tactile sensation, growth factor therapy, gene therapy, stem cell-based therapies, and regenerative medicine. Concurrent use of centrally and peripherally acting therapies could optimize treatment response.
Asunto(s)
Disfunciones Sexuales Fisiológicas/terapia , Disfunciones Sexuales Psicológicas/terapia , Alprostadil/uso terapéutico , Ansiedad/etiología , Afrodisíacos/uso terapéutico , Apomorfina/uso terapéutico , Consenso , Deshidroepiandrosterona/uso terapéutico , Dopamina/fisiología , Agonistas de Dopamina/uso terapéutico , Inhibidores de Captación de Dopamina/uso terapéutico , Medicina Basada en la Evidencia , Femenino , Predicción , Humanos , Melanocortinas/agonistas , Neurotransmisores/uso terapéutico , Donantes de Óxido Nítrico/uso terapéutico , Dolor Pélvico/terapia , Pruebas de Farmacogenómica , Inhibidores de Fosfodiesterasa 5/uso terapéutico , Psicoterapia/métodos , Serotonina/fisiología , Conducta Sexual/psicología , Testosterona/uso terapéutico , Estimulación Magnética Transcraneal/métodosRESUMEN
BACKGROUND: The central melanocortin system is broadly involved in the regulation of mammalian nutrient utilization. However, the function of melanocortin receptors (MCRs) expressed directly in peripheral metabolic tissues is still unclear. The objective of this study was to investigate the lipolytic capacity of MC1-5R in differentiated adipocytes versus intact white adipose tissue. RESULTS: Non-selective MCR agonist α-MSH, MC5R-selective agonist PG-901 and MC4R-selective agonist LY2112688 significantly stimulated lipolysis in intact white adipose tissue, whereas stimulation of MCRs in differentiated adipocytes failed to do so. The lipolytic response of MC5R was decreased in intact human white adipose tissue when co-treating with ß-adrenergic antagonist propranolol, suggesting that the effect may be dependent on neuronal innervation via noradrenalin release. CONCLUSION: When developing an anti-obesity therapeutic drug with selective MC4R/MC5R properties, effects on lipolysis in white adipose tissue may be physiologically relevant.
Asunto(s)
Adipocitos/metabolismo , Tejido Adiposo Blanco/metabolismo , Lipólisis , Melanocortinas/agonistas , Adipocitos/efectos de los fármacos , Tejido Adiposo Blanco/efectos de los fármacos , Ácidos Grasos/metabolismo , Femenino , Glicerol/metabolismo , Humanos , Lipólisis/efectos de los fármacos , Modelos Biológicos , Obesidad/metabolismo , Péptidos Cíclicos/farmacología , Receptores de Melanocortina/metabolismo , Tejido Subcutáneo/efectos de los fármacos , Tejido Subcutáneo/metabolismo , Sinapsis/metabolismoRESUMEN
Although the role of alpha-melanocyte stimulating hormone (α-MSH) in alcohol seeking behaviour in rats has been demonstrated, the underlying mechanisms are not understood. Herein, we test the hypothesis that α-MSH might have a permissive effect in promoting the reward action of ethanol. Rats were implanted with cannulae targeted at the posterior ventral tegmental area (pVTA), because the site is sensitive to reinforcing effects of ethanol. These rats were trained to self-administer ethanol in standard two-lever (active/inactive) operant chamber test. Each active lever press resulted in self-administration of 100 nl of ethanol (100-300 mg%) containing solution. Over a period of 7 days, ethanol significantly increased the number of lever presses, which was considered as a measure of reward. Because ethanol at 200 mg% resulted in maximum number of lever presses (â¼18-20 lever presses/30-minute session), the dose was employed in further studies. While prior administration of melanocortin (MC) agonists, α-MSH or [Nle4,D-Phe7]-alpha-MSH into pVTA, resulted in an 89% increase in lever presses, the response was attenuated following pre-treatment with MC4 receptors (MC4R) antagonist, HS014. In an immunohistochemical study, the brains of rats that were trained to self-infuse ethanol showed significantly increased α-MSH immunoreactivity in the nucleus accumbens shell, bed nucleus of stria terminalis and arcuate nucleus of the hypothalamus. In the pVTA, α-MSH fibres were found to run close to the dopamine cells, labelled with tyrosine hydroxylase antibodies. We suggest that α-MSH-MC4R system in the pVTA might be a part of the neuroadaptive mechanism underlying ethanol addiction.
Asunto(s)
Alcoholismo/metabolismo , Depresores del Sistema Nervioso Central/administración & dosificación , Etanol/administración & dosificación , Receptor de Melanocortina Tipo 4/metabolismo , Refuerzo en Psicología , Área Tegmental Ventral , alfa-MSH/metabolismo , Animales , Núcleo Arqueado del Hipotálamo/metabolismo , Depresores del Sistema Nervioso Central/farmacología , Neuronas Dopaminérgicas/metabolismo , Comportamiento de Búsqueda de Drogas , Etanol/farmacología , Hipotálamo/metabolismo , Inmunohistoquímica , Melanocortinas/agonistas , Microinyecciones , Núcleo Accumbens/metabolismo , Péptidos Cíclicos/farmacología , Ratas , Receptor de Melanocortina Tipo 4/antagonistas & inhibidores , Autoadministración , Núcleos Septales/metabolismo , alfa-MSH/efectos de los fármacosRESUMEN
C-type natriuretic peptide (CNP) and its receptor are abundantly distributed in the brain, especially in the arcuate nucleus (ARC) of the hypothalamus associated with regulating energy homeostasis. To elucidate the possible involvement of CNP in energy regulation, we examined the effects of intracerebroventricular administration of CNP on food intake in mice. The intracerebroventricular administration of CNP-22 and CNP-53 significantly suppressed food intake on 4-h refeeding after 48-h fasting. Next, intracerebroventricular administration of CNP-22 and CNP-53 significantly decreased nocturnal food intake. The increment of food intake induced by neuropeptide Y and ghrelin was markedly suppressed by intracerebroventricular administration of CNP-22 and CNP-53. When SHU9119, an antagonist for melanocortin-3 and melanocortin-4 receptors, was coadministered with CNP-53, the suppressive effect of CNP-53 on refeeding after 48-h fasting was significantly attenuated by SHU9119. Immunohistochemical analysis revealed that intracerebroventricular administration of CNP-53 markedly increased the number of c-Fos-positive cells in the ARC, paraventricular nucleus, dorsomedial hypothalamus, ventromedial hypothalamic nucleus, and lateral hypothalamus. In particular, c-Fos-positive cells in the ARC after intracerebroventricular administration of CNP-53 were coexpressed with α-melanocyte-stimulating hormone immunoreactivity. These results indicated that intracerebroventricular administration of CNP induces an anorexigenic action, in part, via activation of the melanocortin system.
Asunto(s)
Regulación del Apetito , Hipotálamo/metabolismo , Melanocortinas/agonistas , Péptido Natriurético Tipo-C/metabolismo , Neuronas/metabolismo , Receptores de Melanocortina/agonistas , Transducción de Señal , Animales , Regulación del Apetito/efectos de los fármacos , Conducta Animal/efectos de los fármacos , Conducta Alimentaria/efectos de los fármacos , Ghrelina/antagonistas & inhibidores , Ghrelina/metabolismo , Hipotálamo/citología , Hipotálamo/efectos de los fármacos , Inyecciones Intraventriculares , Masculino , Melanocortinas/antagonistas & inhibidores , Melanocortinas/metabolismo , Hormonas Estimuladoras de los Melanocitos/farmacología , Ratones , Ratones Endogámicos C57BL , Péptido Natriurético Tipo-C/administración & dosificación , Péptido Natriurético Tipo-C/antagonistas & inhibidores , Proteínas del Tejido Nervioso/administración & dosificación , Proteínas del Tejido Nervioso/agonistas , Proteínas del Tejido Nervioso/antagonistas & inhibidores , Proteínas del Tejido Nervioso/metabolismo , Neuronas/citología , Neuronas/efectos de los fármacos , Neuropéptido Y/antagonistas & inhibidores , Neuropéptido Y/metabolismo , Isoformas de Proteínas/agonistas , Isoformas de Proteínas/antagonistas & inhibidores , Isoformas de Proteínas/metabolismo , Precursores de Proteínas/administración & dosificación , Precursores de Proteínas/antagonistas & inhibidores , Precursores de Proteínas/metabolismo , Receptores de Melanocortina/antagonistas & inhibidores , Receptores de Melanocortina/metabolismo , Transducción de Señal/efectos de los fármacos , Regulación hacia Arriba/efectos de los fármacos , alfa-MSH/metabolismoRESUMEN
BACKGROUND: Cyclotides are useful scaffolds to stabilize bioactive peptides. RESULTS: Four melanocortin analogues of kalata B1 were synthesized. One is a selective MC4R agonist. CONCLUSION: The analogues retain the native kalata B1 scaffold and introduce a designed pharmacological activity, validating cyclotides as protein engineering scaffolds. SIGNIFICANCE: A novel type of melanocortin agonist has been developed, with potential as a drug lead for treating obesity. Obesity is an increasingly important global health problem that lacks current treatment options. The melanocortin receptor 4 (MC4R) is a target for obesity therapies because its activation triggers appetite suppression and increases energy expenditure. Cyclotides have been suggested as scaffolds for the insertion and stabilization of pharmaceutically active peptides. In this study, we explored the development of appetite-reducing peptides by synthesizing MC4R agonists based on the insertion of the His-Phe-Arg-Trp sequence into the cyclotide kalata B1. The ability of the analogues to fold similarly to kalata B1 but display MC4R activity were investigated. Four peptides were synthesized using t-butoxycarbonyl peptide chemistry with a C-terminal thioester to facilitate backbone cyclization. The structures of the peptides were found to be similar to kalata B1, evaluated by Hα NMR chemical shifts. KB1(GHFRWG;23-28) had a K(i) of 29 nm at the MC4R and was 107 or 314 times more selective over this receptor than MC1R or MC5R, respectively, and had no detectable binding to MC3R. The peptide had higher affinity for the MC4R than the endogenous agonist, α-melanocyte stimulation hormone, but it was less potent at the MC4R, with an EC(50) of 580 nm for activation of the MC4R. In conclusion, we synthesized melanocortin analogues of kalata B1 that preserve the structural scaffold and display receptor binding and functional activity. KB1(GHFRWG;23-28) is potent and selective for the MC4R. This compound validates the use of cyclotides as scaffolds and has the potential to be a new lead for the treatment of obesity.
Asunto(s)
Ciclotidas/agonistas , Ciclotidas/farmacología , Melanocortinas/agonistas , Secuencia de Aminoácidos , Animales , Línea Celular , Cricetinae , Cristalografía por Rayos X , Ciclotidas/síntesis química , Ciclotidas/química , Diseño de Fármacos , Cinética , Melanocortinas/síntesis química , Melanocortinas/química , Melanocortinas/farmacología , Datos de Secuencia Molecular , Estructura Molecular , Receptores de Melanocortina/química , Receptores de Melanocortina/metabolismo , Relación Estructura-ActividadRESUMEN
Synthetic and natural melanocortin (MC) peptides afford inhibitory properties in inflammation and tissue injury, but characterization of receptor involvement is still elusive. We used the agonist AP214 to test MC-dependent anti-inflammatory effects. In zymosan peritonitis, treatment of mice with AP214 (400 to 800 µg/kg) inhibited cell infiltration, an effect retained in MC receptor type 1, or MC(1), mutant mice but lost in MC(3) null mice. In vitro, cytokine release from zymosan-stimulated macrophages was affected by AP214, with approximately 80%, 30%, and 40% reduction in IL-1ß, tumor necrosis factor-α, and IL-6, respectively. Inhibition of IL-1ß release was retained in MC(1) mutant cells but was lost in MC(3) null cells. Furthermore, AP214 augmented uptake of zymosan particles and human apoptotic neutrophils by wild-type macrophages: this proresolving property was lost in MC(3) null macrophages. AP214 displayed its pro-efferocytotic effect also in vivo. Finally, in a model of inflammatory arthritis, AP214 evoked significant reductions in the clinical score. These results indicate that AP214 elicits anti-inflammatory responses, with a preferential effect on IL-1ß release. Furthermore, we describe for the first time a positive modulation of an MC agonist on the process of efferocytosis. In all cases, endogenous MC(3) is the receptor that mediates these novel properties of AP214. These findings might clarify the tissue-protective properties of AP214 in clinical settings and may open further development for novel MC agonists.
Asunto(s)
Artritis Experimental/tratamiento farmacológico , Inflamación/tratamiento farmacológico , Melanocortinas/agonistas , Peritonitis/tratamiento farmacológico , Receptor de Melanocortina Tipo 1/fisiología , Receptor de Melanocortina Tipo 3/fisiología , alfa-MSH/análogos & derivados , Animales , Apoptosis/efectos de los fármacos , Artritis Experimental/metabolismo , Artritis Experimental/patología , Western Blotting , Citocinas/genética , Citocinas/metabolismo , Modelos Animales de Enfermedad , Ensayo de Inmunoadsorción Enzimática , Humanos , Inflamación/metabolismo , Inflamación/patología , Interleucina-1beta/genética , Interleucina-1beta/metabolismo , Interleucina-6/genética , Interleucina-6/metabolismo , Macrófagos/citología , Macrófagos/efectos de los fármacos , Macrófagos/metabolismo , Macrófagos Peritoneales/citología , Macrófagos Peritoneales/efectos de los fármacos , Macrófagos Peritoneales/metabolismo , Masculino , Ratones , Ratones Endogámicos C57BL , Ratones Noqueados , Mutación/genética , Neutrófilos/citología , Neutrófilos/efectos de los fármacos , Neutrófilos/metabolismo , Peritonitis/metabolismo , Peritonitis/patología , Fagocitosis , ARN Mensajero/genética , Reacción en Cadena de la Polimerasa de Transcriptasa Inversa , Factor de Necrosis Tumoral alfa/genética , Factor de Necrosis Tumoral alfa/metabolismo , alfa-MSH/farmacologíaRESUMEN
Impairments in leptin-melanocortin signaling are associated with insulin-deficient diabetes and leptin treatment has been shown to be effective in reversing hyperglycemia in animal models of type 1 diabetes. Therefore, we hypothesized that enhanced central melanocortin signaling reverses the metabolic impairments associated with type 1 diabetes. To address this hypothesis, streptozotocin (STZ)-induced diabetic mice were treated with daily intracerebroventricular injection of MTII, a melanocortin agonist, for 11days. STZ-induced hyperglycemia and glucose intolerance were not improved by MTII treatment. MTII treatment did not alter expression levels of genes encoding gluconeogenic enzymes including glucose-6-phosphatase (G6Pase) and phosphoenolpyruvate carboxykinase (PEPCK), in the liver of diabetic mice. Skeletal muscle and white adipose tissue glucose transporter 4 (GLUT4) mRNA levels were not altered by MTII treatment in diabetic mice. In contrast, serum nonesterified fatty acid (NEFA) levels were significantly increased in STZ-induced diabetic mice compared to non-diabetic control mice and MTII treatment significantly reduced serum NEFA levels in diabetic mice. MTII treatment also significantly reduced expression levels of hormone sensitive lipase (HSL) and adipose triglyceride lipase (ATGL) mRNA in white adipose tissue of diabetic mice without a significant change in serum insulin levels. Expression levels of lipoprotein lipase (LPL) and fatty acid translocase (FAT/CD36) mRNA in white adipose tissue and skeletal muscle were not changed by MTII treatment. These data suggest that central melanocortin signaling regulates lipid metabolism and that enhancing central melanocortin signaling is effective in reversing abnormal lipid metabolism, but not carbohydrate metabolism, at least partly by reducing lipolysis in type 1 diabetes.
Asunto(s)
Diabetes Mellitus Experimental/metabolismo , Metabolismo de los Lípidos/efectos de los fármacos , Melanocortinas/agonistas , alfa-MSH/análogos & derivados , Animales , Glucemia/metabolismo , Peso Corporal , Niño , Ingestión de Alimentos , Humanos , Insulina/sangre , Leptina/sangre , Masculino , Ratones , Ratones Endogámicos C57BL , Triglicéridos/sangre , alfa-MSH/farmacologíaRESUMEN
In the intervening three decades since Panksepp observed for the first time that centrally administered α-melanocyte stimulating hormone decreased food intake (Panksepp and Meeker, 1976), a wealth of data have accrued to firmly establish melanocortin signaling as a central regulator of food intake and fat mass. Advances in molecular biology have not only allowed detailed studies of spontaneously occurring obese mice with altered melanocortin signaling to be undertaken but also permitted the generation of a plethora of mouse models with precise perturbations at critical steps in the melanocortin system to finesse further the cellular and molecular architecture of relevant pathways. In this article we focus in upon a number of these mouse models which continue to help us tease apart the complexities of this critical system. Further, we review data on the important interaction between pro-opiomelanocortin derived peptides and the adrenal system and the relationship between agonist and antagonist peptides acting at central melanocortin receptors.
Asunto(s)
Proteína Relacionada con Agouti/metabolismo , Peso Corporal , Glucocorticoides/metabolismo , Melanocortinas/metabolismo , Proteína Relacionada con Agouti/química , Animales , Peso Corporal/efectos de los fármacos , Grasas de la Dieta , Glucocorticoides/farmacología , Humanos , Melanocortinas/agonistas , Melanocortinas/antagonistas & inhibidores , Melanocortinas/deficiencia , FenotipoRESUMEN
Fasting-induced suppression of thyroid hormone levels is an adaptive response to reduce energy expenditure in both humans and mice. This suppression is mediated by the hypothalamic-pituitary-thyroid axis through a reduction in TRH levels expressed in neurons of the paraventricular nucleus of the hypothalamus (PVN). TRH gene expression is positively regulated by leptin. Whereas decreased leptin levels during fasting lead to a reduction in TRH gene expression, the mechanisms underlying this process are still unclear. Indeed, evidence exists that TRH neurons in the PVN are targeted by leptin indirectly via the arcuate nucleus, whereas correlative evidence for a direct action exists as well. Here we provide both in vivo and in vitro evidence that the activity of hypothalamic-pituitary-thyroid axis is regulated by both direct and indirect leptin regulation. We show that both leptin and α-MSH induce significant neuronal activity mediated through a postsynaptic mechanism in TRH-expressing neurons of PVN. Furthermore, we provide in vivo evidence indicating the contribution of each pathway in maintaining serum levels of thyroid hormone.
Asunto(s)
Adiposidad/fisiología , Neuronas/fisiología , Núcleo Hipotalámico Paraventricular/fisiología , Hormona Liberadora de Tirotropina/biosíntesis , Adiposidad/efectos de los fármacos , Animales , Núcleo Arqueado del Hipotálamo/metabolismo , Ayuno/sangre , Ayuno/metabolismo , Humanos , Sistema Hipotálamo-Hipofisario/efectos de los fármacos , Sistema Hipotálamo-Hipofisario/metabolismo , Leptina/metabolismo , Leptina/farmacología , Melanocortinas/agonistas , Melanocortinas/farmacología , Ratones , Ratones Transgénicos , Neuronas/citología , Neuronas/efectos de los fármacos , Neuronas/metabolismo , Neuropéptido Y/metabolismo , Neuropéptido Y/farmacología , Núcleo Hipotalámico Paraventricular/citología , Núcleo Hipotalámico Paraventricular/efectos de los fármacos , Núcleo Hipotalámico Paraventricular/metabolismo , Hipófisis/efectos de los fármacos , Hipófisis/metabolismo , Ratas , Glándula Tiroides/efectos de los fármacos , Glándula Tiroides/metabolismo , Hormonas Tiroideas/sangre , Hormonas Tiroideas/metabolismo , Hormona Liberadora de Tirotropina/antagonistas & inhibidores , Hormona Liberadora de Tirotropina/genética , alfa-MSH/metabolismo , alfa-MSH/farmacologíaRESUMEN
Structure-activity relationship (SAR) studies are a key feature of peptide and peptidomimetic research to improve the biological properties of native peptides and convert them into more drug-like compounds. Peptide SAR studies involve the systematic modification of a lead peptide to provide insight into the molecular determinants of the ligand-receptor interactions that result in either receptor stimulation or inhibition. This chapter will discuss structure-activity relationships of the endogenous and synthetic agonists and the antagonists of the melanocortin system.
Asunto(s)
Proteína Relacionada con Agouti/química , Proteína Relacionada con Agouti/metabolismo , Melanocortinas/química , Melanocortinas/metabolismo , Fragmentos de Péptidos/química , Fragmentos de Péptidos/metabolismo , Secuencia de Aminoácidos , Animales , Descubrimiento de Drogas , Humanos , Melanocortinas/agonistas , Melanocortinas/antagonistas & inhibidores , Datos de Secuencia Molecular , Relación Estructura-ActividadRESUMEN
Female sexual dysfunction (FSD) incorporates various sexual disorders including hypoactive sexual desire disorder, sexual arousal disorder, orgasmic and sexual pain disorders. Although many strategies have been formulated for the treatment of male sexual problems, FSD remains an area that warrants further research and trial studies to identify the most efficacious treatment options. Research has highlighted numerous pharmacological interventions that have been trialled and found to exhibit positive effects. These include hormonal therapies, prostaglandins, dopaminergic agonists, phosphodiesterase type-5 (PDE-5) inhibitors and melanocortin agonists.
Asunto(s)
Disfunciones Sexuales Fisiológicas/tratamiento farmacológico , Agonistas de Dopamina/uso terapéutico , Femenino , Hormonas/uso terapéutico , Humanos , Melanocortinas/agonistas , Melanocortinas/farmacología , Piperazinas/uso terapéutico , Prostaglandinas/uso terapéutico , Purinas/uso terapéutico , Citrato de Sildenafil , Sulfonas/uso terapéutico , Vasodilatadores/uso terapéuticoRESUMEN
2mg/kg melanotan II (MTII, administered i.p.), a cyclic peptide analog of alpha-melanocyte stimulating hormone, at a single dose increased grooming in naive rats placed in an unfamiliar open-field device without changing locomotion or rearing. Male rats exposed to restraint/immobilization stress (IS) for 1h on three consecutive days displayed increased grooming after the second stressor exposure, compared to pre-stress levels. MTII, administered to the rats after IS, enhanced the grooming response compared both to the pre- and post-stress values. The increase was greatest after the first dose and declined over the following two applications. As to the locomotion of rats in the entire experimental space, IS reduced the distance moved only after the first two stressor exposures; MTII did not influence these alterations. Locomotion in the central part of arena was not reduced by the stressor or by MTII, on the contrary, there was an increase in both groups after the third intervention. The only observed change in rearing was an increase in the MTII group after the third restraint exposure. Thus, MTII selectively increased grooming without markedly affecting the spatio-temporal structure of locomotor behavior in the open-field. The decline of MTII enhanced grooming over the three test days may be interpreted in terms of adaptation to the stressor and of the developing tolerance to the peptide.
Asunto(s)
Conducta Exploratoria/efectos de los fármacos , Aseo Animal/efectos de los fármacos , Péptidos Cíclicos/farmacología , Restricción Física , alfa-MSH/análogos & derivados , Animales , Conducta Animal , Conducta Exploratoria/fisiología , Aseo Animal/fisiología , Masculino , Melanocortinas/agonistas , Actividad Motora/efectos de los fármacos , Ratas , Ratas Wistar , alfa-MSH/farmacologíaRESUMEN
The central melanocortin system plays a critical role in regulation of energy balance, including thermogenesis in brown adipose tissue (BAT). Activation of the hypothalamic melanocortin signaling stimulates sympathetically-mediated interscapular BAT (IBAT) thermogenesis. The rostral raphe pallidus (rRPa) and adjacent area have been proposed as the location of sympathetic premotor neurons for the central nervous system (CNS) control of IBAT thermogenesis. To determine if neuronal activity in rRPa area is required for the central melanocortin-induced thermogenesis, we studied the effects of inhibition of the activity of neurons in the rRPa area on the sympathetic nerve activity (SNA) to IBAT evoked by lateral ventricular injection of the melanocortin 3/4 receptor (MC3/4R) agonist, MTII, in urethane-chloralose-anesthetized rats and the effects on O(2) consumption induced by third or fourth ventricular injection of MTII in conscious freely moving mice. Icv injection of MTII (1 nmol) significantly increased rat IBAT SNA (+741% of control). Both third and fourth ventricular injections of MTII (1 nmol) significantly increased O(2) consumption in conscious C57BL/6J mice (45% higher than that of saline control for third ventricular injection and 44% higher than that of saline control for fourth ventricular injection). The increases in IBAT SNA and in O(2) consumption were reversed by inhibition of neurons in the rRPa and adjacent area with microinjections of glycine or muscimol into rRPa. These results suggest that the neurons in the RPa and its immediate vicinity play an essential role in mediating the increase in IBAT thermogenesis induced by activation of central melanocortin signaling.
Asunto(s)
Melanocortinas/agonistas , Neuronas/fisiología , Núcleos del Rafe/fisiología , Termogénesis/fisiología , alfa-MSH/análogos & derivados , Tejido Adiposo Pardo/efectos de los fármacos , Tejido Adiposo Pardo/fisiología , Animales , Interpretación Estadística de Datos , Inyecciones Intraventriculares , Masculino , Ratones , Ratones Endogámicos C57BL , Neuronas/efectos de los fármacos , Consumo de Oxígeno/efectos de los fármacos , Núcleos del Rafe/citología , Núcleos del Rafe/efectos de los fármacos , Ratas , Ratas Sprague-Dawley , Transducción de Señal/efectos de los fármacos , Transducción de Señal/fisiología , Sistema Nervioso Simpático/efectos de los fármacos , Sistema Nervioso Simpático/fisiología , Termogénesis/efectos de los fármacos , alfa-MSH/farmacologíaRESUMEN
The melanocortin type 1 receptor (Mc1r) belongs to a family of G-protein-coupled receptors involved in various physiological processes in vertebrates. Melanocortins, the Mcr natural agonists, are pituitary peptide hormones including adrenocorticotropin and melanocyte-stimulating hormones. In mammals and birds, Mc1r is involved in pigmentation and expressed in melanocytes and melanoma. Activation of Mc1r leads to eumelanin production as well as to proliferation and survival of melanocytes in the epidermis. Here we report the molecular and evolutionary analysis of mc1r from three major fish models, the zebrafish Danio rerio, the medaka Oryzias latipes and the platyfish Xiphophorus maculatus. In contrast to some other melanocortin receptor genes, mc1r has been conserved as a single copy gene in divergent fish species. Its expression was detected in all organs tested in platyfish and medaka but was restricted to eyes, skin, brain and testis in zebrafish, this possibly reflecting differences in the distribution of extracutaneous melanophores. The mc1r gene was found to be expressed during embryogenesis, as well as in Xiphophorus hybrid melanoma, similar to human tumours. Protein sequence comparison between fish and mammalian Mc1r revealed a remarkable concordance between evolutionary and functional analyses for the identification of residues and regions critical for receptor function.
Asunto(s)
Ciprinodontiformes/genética , Evolución Molecular , Oryzias/genética , Receptor de Melanocortina Tipo 1/metabolismo , Pez Cebra/genética , Secuencia de Aminoácidos , Sustitución de Aminoácidos , Animales , Línea Celular , Clonación Molecular , Dosificación de Gen , Melanocortinas/agonistas , Melanocortinas/genética , Melanocortinas/metabolismo , Melanoma Experimental , Melanóforos/metabolismo , Modelos Genéticos , Datos de Secuencia Molecular , Filogenia , Estructura Terciaria de Proteína , Receptor de Melanocortina Tipo 1/química , Receptor de Melanocortina Tipo 1/genética , Análisis de Secuencia de Proteína , Homología de Secuencia de AminoácidoRESUMEN
The melanocortin system has been implicated in regulating various physiological processes including pigmentation, energy homeostasis, obesity, steroidogenesis cardiovascular, and exocrine gland function. The five melanocortin receptors that belong to the super family of G protein-coupled receptors are stimulated by naturally occurring agonists. The aim of this research was focused on the design, synthesis, and pharmacological characterization of melanocortin ligands that contain the 1,2,5-trisubstituted benzimidazole scaffold. A series of benzimidazole analogues, with three points of diversity at positions 1, 2, and 5, were designed, synthesized, pharmacologically assayed at the mouse melanocortin receptors MC1R, MC3R, MC4R, and MC5R and resulted in ligands possessing a range of agonist activity from nm to no stimulation at up to 100 microM concentrations. This study demonstrates that the benzimidazole structure template can be appended with key melanocortin agonist amino acids for the design melanocortin receptor agonist ligands.
Asunto(s)
Bencimidazoles/farmacología , Melanocortinas/agonistas , Bencimidazoles/química , Línea Celular , Humanos , Relación Estructura-ActividadRESUMEN
The melanocortin system is a critical pathway in the regulation of energy balance. In this study, we analyzed the peripheral effects of the synthetic melanocortin agonist melanotan-II (MT-II) in rodents fed a low-fat or high-fat diet. MT-II-treated high-fat diet-induced obese (DIO) mice lost weight and body fat, whereas MT-II-treated low-fat-fed mice maintained their original body weight. Specifically, MT-II treatment led to a general reduction in both visceral and subcutaneous adipose tissue in high-fat-fed mice compared with Vehicle (ad libitum) controls. Vehicle-treated pair-fed DIO mice lost an equivalent amount of body weight compared with MT-II-treated mice but retained more adipose tissue. Pair-fed mice showed a reduction in visceral adipose tissue and no effect on subcutaneous adipose tissue compared with MT-II-treated mice. It is surprising that subcutaneous lean mass was significantly reduced in the pairfed mice. The data were replicated in DIO rats and indicated that MT-II treatment led to a generalized reduction in adipose tissue. These results indicate that peripheral MT-II treatment leads to weight loss that affects both the visceral and subcutaneous fat compartments. This finding illustrates the complexity of analyzing weight-reducing compounds. Although the present data suggest that the anorectic effect of MT-II is primarily a consequence of reduced food intake, the body composition data suggest that other mechanisms are involved.
Asunto(s)
Grasa Intraabdominal/efectos de los fármacos , Melanocortinas/agonistas , Péptidos Cíclicos/farmacología , Grasa Subcutánea/efectos de los fármacos , alfa-MSH/análogos & derivados , Animales , Peso Corporal/efectos de los fármacos , Ratones , Ratones Obesos , Obesidad/tratamiento farmacológico , alfa-MSH/farmacologíaRESUMEN
Little is known about the role of the central melanocortin system in the control of fuel metabolism in peripheral tissues. Skeletal muscle AMP-activated protein kinase (AMPK) is activated by leptin and serves as a master regulator of fatty acid beta-oxidation. To elucidate an unidentified role of the central melanocortin system in muscle AMPK regulation, we treated conscious, unrestrained mice intracerebroventricularly with the melanocortin agonist MT-II or the antagonist SHU9119. MT-II augmented phosphorylation of AMPK and its target acetyl-CoA carboxylase (ACC) independent of caloric intake. Conversely, AMPK/ACC phosphorylation by leptin was abrogated by the coadministration of SHU9119 or in KKA(y) mice, which centrally express endogenous melanocortin antagonist. Importantly, high-fat-diet-induced attenuation of AMPK/ACC phosphorylation in leptin-overexpressing transgenic mice was not reversed by central leptin but was markedly restored by MT-II. Our data provide evidence for the critical role of the central melanocortin system in the leptin-skeletal muscle AMPK axis and highlight the system as a therapeutic target in leptin resistance.
Asunto(s)
Melanocortinas/metabolismo , Músculo Esquelético/metabolismo , Proteínas Quinasas/metabolismo , Transducción de Señal/fisiología , Quinasas de la Proteína-Quinasa Activada por el AMP , Análisis de Varianza , Animales , Western Blotting , Grasas de la Dieta , Leptina/metabolismo , Melanocortinas/agonistas , Melanocortinas/antagonistas & inhibidores , Hormonas Estimuladoras de los Melanocitos/farmacología , Metalotioneína/farmacología , Ratones , Fosforilación/efectos de los fármacosRESUMEN
In this study, we examined the effects of intracerebroventricular administration of melanotan II (MTII), a melanocortin agonist, on insulin sensitivity in diet-induced obese (DIO) rats. Although MTII treatment significantly decreased food intake and body weight for 10 days, there was no significant difference in body weight between MTII and pair-fed groups. The insulin tolerance test showed that insulin sensitivity was significantly improved in the MTII group compared to the pair-fed group. Furthermore, MTII treatment increased the number of small-sized adipocytes in epididymal white adipose tissues, suggesting that MTII increased insulin sensitivity through action on the white adipose tissues in DIO rats.